Nicola Di Santo

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

Neeraj Agarwal, Arun Azad, Joan Carles et al. · The Lancet · 2023 · 453 citations

Urology, Medicine, Pharmacology +5

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

Karim Fizazi, Arun Azad, Nobuaki Matsubara et al. · Nature Medicine · 2023 · 113 citations · Full text

Retrospective review of an intraoperative algorithm to predict lymph node metastasis in low-grade endometrial adenocarcinoma

P. Convery, Leigh A. Cantrell, Nicola Di Santo et al. · Gynecologic Oncology · 2011 · 83 citations

Surgical Oncology, Gynecological Surgery, Medicine +9

Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design

Neeraj Agarwal, Arun Azad, Neal D. Shore et al. · Future Oncology · 2022 · 55 citations · Full text

Medicinal Chemistry, Urology, Genitourinary Cancer +12

Performance of sentinel lymph node biopsy in high-risk endometrial cancer

Jessie Ehrisman, Angeles Alvarez Secord, Andrew Berchuck et al. · Gynecologic Oncology Reports · 2016 · 54 citations · Full text